Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.
- 15 December 1992
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 89 (24) , 12043-12047
- https://doi.org/10.1073/pnas.89.24.12043
Abstract
Advanced glycosylation end products (AGEs) have been implicated in many of the complications of diabetes and normal aging. Markedly elevated vascular tissue and circulating AGEs were linked recently to the accelerated vasculopathy of end-stage diabetic renal disease. To determine the pathogenic role of AGEs in vivo, AGE-modified albumin was administered to healthy nondiabetic rats and rabbits alone or in combination with the AGE-crosslink inhibitor aminoguanidine. Within 2-4 weeks of AGE treatment, the AGE content of aortic tissue samples rose to six times the amount found in controls (P < 0.001). Cotreatment with aminoguanidine limited tissue AGE accumulation to levels two times that of control. AGE administration was associated with a significant increase in vascular permeability, as assessed by 125I label tracer methods. This alteration was absent in animals that received aminoguanidine in addition to AGE. Significant mononuclear cell migratory activity was observed in subendothelial and periarteriolar spaces in various tissues from AGE-treated rats compared to normal cellularity noted in tissues from animals treated with aminoguanidine. Blood pressure studies of AGE-treated rats and rabbits revealed markedly defective vasodilatory responses to acetylcholine and nitroglycerin compared to controls (P < 0.001), consistent with marked NO. inactivation; aminoguanidine treatment significantly prevented this defect. These in vivo data demonstrate directly that AGEs, independent of metabolic or genetic factors, can induce complex vascular alterations resembling those seen in diabetes or aging. AGE administration represents an animal model system for the study of diabetic and aging complications as well as for assessing the efficacy of newly emerging therapies aimed at inhibiting advanced glycosylation.Keywords
This publication has 21 references indexed in Scilit:
- Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins.Journal of Clinical Investigation, 1992
- Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor.Proceedings of the National Academy of Sciences, 1992
- Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline.Journal of Clinical Investigation, 1992
- Immunochemical detection of advanced glycosylation end products in vivo.Journal of Biological Chemistry, 1992
- Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.Proceedings of the National Academy of Sciences, 1991
- Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins.The Journal of Experimental Medicine, 1991
- Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1990
- Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-LinkingScience, 1986
- Accelerated age-related browning of human collagen in diabetes mellitus.Proceedings of the National Academy of Sciences, 1984
- Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen. Role in the in situ formation of immune complexes.The Journal of Experimental Medicine, 1983